Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis
ChemMedChem · 2024
DOI: 10.1002/cmdc.202300644 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Ehsan Sayyah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Computational Biology and Molecular Simulations Lab, Department of Biophysics, School of Medicine, Bahçeşehir University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Protein Kinase Inhibitors, Quantitative Structure-Activity Relationship, Proto-Oncogene Mas. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Scientific Research Projects Commission of Bahçesehir, University (BAU), T.C. Istanbul Development Agency.
Abstract (Originalsprache)
Activation of RET tyrosine kinase plays a critical role in the pathogenesis of various cancers, including non‐small cell lung cancer, papillary thyroid cancers, multiple endocrine neoplasia type 2A and 2B (MEN2A, MEN2B), and familial medullary thyroid cancer. Gene fusions and point mutations in the RET proto‐oncogene result in constitutive activation of RET signaling pathways. Consequently, developing effective inhibitors to target RET is of utmost importance. Small molecules have shown promise as inhibitors by binding to the kinase domain of RET and blocking its enzymatic activity. However, the emergence of resistance due to single amino acid changes poses a significant challenge. In this study, a structure‐based dynamic pharmacophore‐driven approach using E‐pharmacophore modeling from molecular dynamics trajectories is proposed to select low‐energy favorable hypotheses, and ML‐trained QSAR models to predict pIC 50 values of compounds. For this aim, extensive small molecule libraries were screened using developed ligand‐based models, and potent compounds that are capable of inhibiting RET activation were proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Computational Biology and Molecular Simulations Lab, Department of Biophysics, School of Medicine, Bahçeşehir University, Istanbul, Turkey.
- Computational Drug Design Center (HITMER), Bahçeşehir University, Istanbul, Turkey.
- Department of Biostatistics and Medical Informatics, School of Medicine, Bahçeşehir University, Istanbul, Turkey.
- Molecular Therapy Lab, Department of Pharmaceutical Chemistry, School of Pharmacy, Bahçeşehir University, Istanbul, Turkey.
ORCID-Profile: Serdar Durdagi
Förderung
- Scientific Research Projects Commission of Bahçesehir, University (BAU)
- T.C. Istanbul Development Agency
Zitieren
APA
Sayyah, E., Oktay, L., Tunc, H., & Durdagi, S. (2024). Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis. ChemMedChem. https://doi.org/10.1002/cmdc.202300644
Vancouver
Sayyah E, Oktay L, Tunc H, Durdagi S. Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis. ChemMedChem. 2024. doi:10.1002/cmdc.202300644
BibTeX
@article{Sayyah2024,
author = {Sayyah, Ehsan and Oktay, Lalehan and Tunc, Huseyin and Durdagi, Serdar},
title = {Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202300644}
}
EUVIMED